Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
106M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
43.4M
-
Shares change
-
-104K
-
Total reported value, excl. options
-
$141M
-
Value change
-
+$5.13M
-
Put/Call ratio
-
2.4
-
Number of buys
-
52
-
Number of sells
-
-65
-
Price
-
$3.24
Significant Holders of Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) as of Q3 2024
146 filings reported holding AMLX - Amylyx Pharmaceuticals, Inc. - COMMON STOCK as of Q3 2024.
Amylyx Pharmaceuticals, Inc. - COMMON STOCK (AMLX) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.4M shares
of 106M outstanding shares and own 40.82% of the company stock.
Largest 10 shareholders include TCG Crossover Management, LLC (4.64M shares), VANGUARD GROUP INC (3.09M shares), BlackRock, Inc. (2.55M shares), PERCEPTIVE ADVISORS LLC (2.13M shares), Alyeska Investment Group, L.P. (2.02M shares), 683 Capital Management, LLC (2M shares), Almitas Capital LLC (1.99M shares), abrdn plc (1.97M shares), CITADEL ADVISORS LLC (1.9M shares), and ACADIAN ASSET MANAGEMENT LLC (1.77M shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.